- Home
- EML vs TVGN Comparison
EML vs TVGN Comparison
Compare EML & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- TVGN
- Stock Information
- Founded
- EML 1858
- TVGN 2020
- Country
- EML United States
- TVGN United States
- Employees
- EML N/A
- TVGN N/A
- Industry
- EML Industrial Machinery/Components
- TVGN Blank Checks
- Sector
- EML Consumer Discretionary
- TVGN Finance
- Exchange
- EML Nasdaq
- TVGN Nasdaq
- Market Cap
- EML 141.7M
- TVGN 193.1M
- IPO Year
- EML N/A
- TVGN N/A
- Fundamental
- Price
- EML $23.05
- TVGN $1.24
- Analyst Decision
- EML
- TVGN Strong Buy
- Analyst Count
- EML 0
- TVGN 1
- Target Price
- EML N/A
- TVGN $10.00
- AVG Volume (30 Days)
- EML 12.1K
- TVGN 742.2K
- Earning Date
- EML 08-05-2025
- TVGN 08-13-2025
- Dividend Yield
- EML 1.93%
- TVGN N/A
- EPS Growth
- EML N/A
- TVGN N/A
- EPS
- EML N/A
- TVGN N/A
- Revenue
- EML $271,440,503.00
- TVGN N/A
- Revenue This Year
- EML $1.56
- TVGN N/A
- Revenue Next Year
- EML $7.00
- TVGN N/A
- P/E Ratio
- EML $10.87
- TVGN N/A
- Revenue Growth
- EML 8.15
- TVGN N/A
- 52 Week Low
- EML $19.06
- TVGN $0.26
- 52 Week High
- EML $35.03
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- EML 50.16
- TVGN 49.77
- Support Level
- EML $22.72
- TVGN $1.14
- Resistance Level
- EML $23.79
- TVGN $1.28
- Average True Range (ATR)
- EML 0.57
- TVGN 0.06
- MACD
- EML -0.05
- TVGN -0.01
- Stochastic Oscillator
- EML 63.15
- TVGN 34.88
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.